SU6 Stock Overview
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Surmodics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.80 |
| 52 Week High | US$35.20 |
| 52 Week Low | US$16.20 |
| Beta | 1.02 |
| 1 Month Change | 20.16% |
| 3 Month Change | 5.67% |
| 1 Year Change | 56.84% |
| 3 Year Change | -34.36% |
| 5 Year Change | -17.10% |
| Change since IPO | 52.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| SU6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 23.1% | -0.5% | -0.3% |
| 1Y | 56.8% | -10.1% | 2.8% |
Return vs Industry: SU6 exceeded the German Medical Equipment industry which returned -11.2% over the past year.
Return vs Market: SU6 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| SU6 volatility | |
|---|---|
| SU6 Average Weekly Movement | 11.5% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SU6 has not had significant price volatility in the past 3 months.
Volatility Over Time: SU6's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 376 | Gary Maharaj | www.surmodics.com |
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.
Surmodics, Inc. Fundamentals Summary
| SU6 fundamental statistics | |
|---|---|
| Market cap | €430.23m |
| Earnings (TTM) | €12.54m |
| Revenue (TTM) | €132.76m |
34.3x
P/E Ratio3.2x
P/S RatioIs SU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SU6 income statement (TTM) | |
|---|---|
| Revenue | US$142.96m |
| Cost of Revenue | US$23.09m |
| Gross Profit | US$119.87m |
| Other Expenses | US$106.37m |
| Earnings | US$13.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.95 |
| Gross Margin | 83.85% |
| Net Profit Margin | 9.44% |
| Debt/Equity Ratio | 23.8% |
How did SU6 perform over the long term?
See historical performance and comparison